Dermatology practices biopsy skin lesions constantly, and payers know it. The high transaction volume makes the category a natural target for aggressive bundling edits and strict medical-necessity screening. Individual biopsy claims are often modest, typically $150 to $350 per site, but the denial rate across a busy practice adds up fast. There are four specific patterns that drive the majority of these denials. Each one has a distinct fix.
The four denial patterns in dermatology biopsy billing
1. E/M bundled into the biopsy code (CO-97). When a patient presents and the provider both evaluates their skin condition and performs a biopsy during the same visit, payers frequently bundle the evaluation and management service into the biopsy procedure using CO-97. Their logic: the visit was just the decision to biopsy, so it’s included in the procedure.
The fix is modifier 25 on the E/M. Modifier 25 signals a significant, separately identifiable evaluation and management service on the same day as a procedure. It is legitimate when the provider addressed the patient’s overall skin condition, examined other lesions, reviewed medications, or evaluated concerns that went beyond the specific lesion being biopsied. The documentation has to carry the weight: the E/M note must stand on its own. If the encounter was purely “patient came in for this lesion, provider looked at it, biopsied it,” modifier 25 is harder to sustain. If the note covers a broader clinical picture, it is defensible.
2. Multiple biopsies collapsed to one payment. When the provider biopsies several distinct lesions in one visit, some payers pay the first site and bundle the rest as if they were duplicates. That logic is wrong. CPT includes add-on codes specifically for additional biopsy sites in the same session: 11103 for each additional tangential biopsy beyond the first, 11105 for each additional punch biopsy, and 11107 for each additional incisional biopsy. These add-on codes require no separate modifier; they are designed to accompany the primary code.
An appeal for this denial should cite the CPT add-on code rationale and include documentation confirming distinct anatomic sites, separate clinical concerns per lesion, and separate pathology requisitions. Each specimen sent to pathology as its own submission is the clearest evidence that the sites were genuinely independent.
3. Medical necessity denials (CO-50). CO-50 means the payer does not consider the biopsy medically necessary based on what was submitted. This is the hardest type to recover because it requires actual clinical documentation rather than a coding correction.
A successful CO-50 appeal needs to answer one question: why was a biopsy necessary rather than clinical observation? The documentation should include the lesion’s physical characteristics (morphology, size, color variation, border irregularity), location, duration, any documented change since a prior visit, and the provider’s explicit clinical concern, typically suspicion of melanoma, squamous cell carcinoma, or another malignancy. Payers want to see that specific clinical findings drove the biopsy decision. A note that records only that a biopsy was performed, without the indication, will not sustain the appeal.
4. Modifier errors (CO-4). Derm biopsy claims produce CO-4 denials in two specific situations: modifier 25 missing on the E/M when the payer’s bundling rule requires it, or modifier 59 (or an X modifier) missing when the payer’s system is treating additional sites as duplicates instead of reading the add-on codes correctly. Both are corrected claims. Resubmit with the correct modifier within the payer’s timely filing window rather than going through a formal reconsideration process.
The write-off trap in derm billing
Per-site biopsy payments are modest. A denied biopsy at $175 looks like a small loss in isolation. What makes it significant is the pattern. A practice that biopsies 80 lesions per week and has a 15% denial rate is looking at roughly 12 denied claims per week. At $175 average, that’s about $2,100 weekly and over $100,000 annually before the modifier 25 E/M bundling losses are added on top.
Most of those denials fall below the threshold where manual case-by-case review is economically rational. This is the small-claim appeal problem in concentrated form: too many to work individually, too consistent in their cause to justify discarding them. The right approach is to detect the pattern, build a response template by CARC code, and work them in batches. See the revenue leakage guide for the broader framework on finding and prioritizing unworked denial inventory.
Upstream habits that prevent most of these denials
- Attach modifier 25 at the time of billing when the documentation supports it. Don’t wait for the CO-97 denial. If the note covers the patient’s skin condition more broadly than the biopsied lesion, modifier 25 belongs on the claim from the start.
- Use the correct add-on CPT code for every additional biopsy site. Submitting only the primary code for a three-site session leaves two sites uncompensated. Each additional punch, tangential, or incisional biopsy has a specific add-on code.
- Document the clinical indication before the biopsy, in the pre-procedure note. Lesion characteristics, patient history of changing moles, relevant family history, and the specific clinical concern should be in the chart before the biopsy is performed. Adding that context retroactively after a CO-50 denial is harder to do and less persuasive.
- Record each specimen as a distinct anatomic site. When multiple lesions are biopsied, the clinical note should identify each site separately. The pathology lab will log separate accession numbers; the chart should reflect the same granularity.
For Texas dermatology practices
When a state-regulated commercial payer in Texas wrongly denies or delays payment on a clean biopsy claim, prompt-pay provisions give providers real tools. For high-volume practices where a pattern of denials affects hundreds of claims, the Texas Prompt Pay Act framework is worth running alongside the denial analysis to see the full statutory interest exposure on late or incorrectly paid claims.
Working the volume
Dermatology biopsy denials are almost always fixable. CO-97 E/M bundling resolves with modifier 25 and supporting documentation. Multiple-site collapsing corrects via a resubmission with add-on codes and anatomic site evidence. CO-50 denials need clinical documentation pulled and organized into a structured appeal letter. CO-4 modifier errors are corrected claims. The challenge is not the individual fix; it is handling the volume. The same denial reasons repeat across hundreds of claims per month. Building a response template for each CARC code and processing them in batches converts this from an unmanageable backlog into a manageable one.